{"title":"青光眼的神经保护与再生。","authors":"Leonard A Levin","doi":"10.1016/j.ohc.2005.07.001","DOIUrl":null,"url":null,"abstract":"<p><p>Glaucoma is the most common optic neuropathy. Preventing visual loss is being studied with neuroprotective therapies. Visual restoration requires a restoration of retinal ganglion cells and their axons, ie, neurorepair and neuroregeneration. This review surveys recent developments in neuroprotection and regeneration from the standpoint of eventual applicability to treatment of patients who have glaucoma.</p>","PeriodicalId":82231,"journal":{"name":"Ophthalmology clinics of North America","volume":"18 4","pages":"585-96, vii"},"PeriodicalIF":0.0000,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"30","resultStr":"{\"title\":\"Neuroprotection and regeneration in glaucoma.\",\"authors\":\"Leonard A Levin\",\"doi\":\"10.1016/j.ohc.2005.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glaucoma is the most common optic neuropathy. Preventing visual loss is being studied with neuroprotective therapies. Visual restoration requires a restoration of retinal ganglion cells and their axons, ie, neurorepair and neuroregeneration. This review surveys recent developments in neuroprotection and regeneration from the standpoint of eventual applicability to treatment of patients who have glaucoma.</p>\",\"PeriodicalId\":82231,\"journal\":{\"name\":\"Ophthalmology clinics of North America\",\"volume\":\"18 4\",\"pages\":\"585-96, vii\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2005-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"30\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmology clinics of North America\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ohc.2005.07.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology clinics of North America","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ohc.2005.07.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Glaucoma is the most common optic neuropathy. Preventing visual loss is being studied with neuroprotective therapies. Visual restoration requires a restoration of retinal ganglion cells and their axons, ie, neurorepair and neuroregeneration. This review surveys recent developments in neuroprotection and regeneration from the standpoint of eventual applicability to treatment of patients who have glaucoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
